Sign In
Buy STTK
$4.75
-0.120 (-2.46%)
At Close: Jun 03, 2026
Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252
04:30pm, Wednesday, 11'th Aug 2021
– Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immu
Shattuck Labs Announces Participation in the BTIG Biotechnology Conference
10:40am, Friday, 06'th Aug 2021
AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p
Shattuck Labs Appoints Abhinav A. Shukla as Chief Technical Officer
10:44am, Tuesday, 01'st Jun 2021
AUSTIN, TX and DURHAM, NC, June 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs Announces Participation in Upcoming May Conferences
05:33pm, Friday, 30'th Apr 2021
AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p
Shattuck Labs Announces Participation in the 7th Annual Truist Securities Life Sciences Summit
04:45pm, Wednesday, 28'th Apr 2021
AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fus
Shattuck Labs Announces Promotion of Andrew R. Neill to Chief Financial Officer
07:00am, Tuesday, 16'th Mar 2021
AUSTIN, TX and DURHAM, NC, March 16, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion
Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
04:45pm, Monday, 15'th Mar 2021
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 –
Shattuck Labs to Present Two Posters at the 2021 American Association for Cancer Research (AACR) Annual Meeting
08:28am, Thursday, 11'th Mar 2021
AUSTIN, TX and DURHAM, NC, March 11, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p
Shattuck Labs Announces Participation in Upcoming March Investor Conferences
06:40pm, Tuesday, 23'rd Feb 2021
AUSTIN, TX and DURHAM, NC, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs Announces Participation in Citi's 2021 Virtual Immuno-Oncology Day
09:41am, Friday, 12'th Feb 2021
AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion prot
Shattuck Labs to Present at H.C. Wainwright BioConnect 2021 Conference
05:27pm, Thursday, 07'th Jan 2021
AUSTIN, TX and DURHAM, NC, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs to Present at 39th Annual J.P. Morgan Healthcare Conference
08:23am, Wednesday, 06'th Jan 2021
AUSTIN, TX and DURHAM, NC, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs Added to Russell 2000® and 3000® Indexes
06:42pm, Friday, 18'th Dec 2020
AUSTIN, TX and DURHAM, NC, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference
04:30pm, Wednesday, 25'th Nov 2020
AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr
Shattuck Labs Reports Third Quarter 2020 Financial Results and Recent Business Highlights
06:00am, Friday, 13'th Nov 2020
– Initiated Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), for the treatment of ovarian cancer –
